BioCentury | Feb 7, 2011
Product Development

Obesity Reset

...Preclin Palatin Technologies Inc. (NYSE-A:PTN)/AstraZeneca plc (LSE:AZN; NYSE:AZN) MCR agonist Melanocortin receptor (MCR) agonist Preclin Phynova Group plc...
BioCentury | Aug 3, 2009
Financial News

Phynova financial update

...company expects its shares to be delisted on Aug. 24, if shareholders approve the proposal. Phynova Group plc...
BioCentury | Jun 22, 2009
Financial News

Phynova completes private placement of common stock and warrants

Phynova Group plc (LSE:PYN; Pink:PHNVY), Oxford, U.K. Business: Infectious, Metabolic, Cancer Date completed: 6/15/09 Type: Private placement of common stock and warrants Raised: £3,000 ($4,896) Shares: 50,000 Price: 6p Shares after offering: 31.7 million Investors:...
BioCentury | Nov 24, 2008
Company News

Norgine, Phynova deal

...from Phynova to treat liver disease, after which the companies will consider further collaborative work. Phynova's...
...diagnose liver diseases such as non-alcoholic steatohepatitis (NASH) and hepatitis. Norgine B.V. , Harefield, U.K. Phynova Group plc...
BioCentury | Oct 27, 2008
Clinical News

Phynova preclinical data

...treat MRSA. Phynova licensed the compound from Botanic Century Co. Ltd. (Beijing, China) in 2006. Phynova Group plc...
BioCentury | Aug 28, 2008
Tools & Techniques

Paths of Yeast Assistance

...synthesized at high yields in a well-controlled process. Tony Mills, director of business development at Phynova Group plc...
...research tool for characterizing the enzymes that produce pharmacologically active compounds in a particular plant. Phynova...
...a Phase IIb trial in the near future, though Mills declined to provide a timeline. Phynova...
BioCentury | May 26, 2008
Finance

Midlife crisis

...the costs of Sarbanes-Oxley compliance against low trading volume. One workaround is being pursued by Phynova Group plc...
...expensive burden of compliance with Sarbanes-Oxley," CEO Robert Miller told BioCentury. Originally backed by angels, Phynova...
...is about to enter Phase IIb trials, with proof of concept data expected next year. Phynova...
BioCentury | May 26, 2008
Finance

Late-stage opportunities

...LSE:OXB) -45% Algeta (OSE:ALGETA) -45% Antisoma (LSE:ASM) -41% Exonhit (Euronext:ALEHT) -44% AMT (Euronext:AMT) (B) -37% Phynova...
BioCentury | Dec 10, 2007
Clinical News

Phynova preclinical data

...in Munich. PYN licensed the compound from Botanic Century Co. Ltd. (Beijing, China) in 2006. Phynova Group plc...
BioCentury | Dec 3, 2007
Finance

Ebb & Flow II

...the small molecule CC chemokine receptor 1 (CCR1) antagonist under a 2000 deal (see B25). Phynova...
Items per page:
1 - 10 of 23
BioCentury | Feb 7, 2011
Product Development

Obesity Reset

...Preclin Palatin Technologies Inc. (NYSE-A:PTN)/AstraZeneca plc (LSE:AZN; NYSE:AZN) MCR agonist Melanocortin receptor (MCR) agonist Preclin Phynova Group plc...
BioCentury | Aug 3, 2009
Financial News

Phynova financial update

...company expects its shares to be delisted on Aug. 24, if shareholders approve the proposal. Phynova Group plc...
BioCentury | Jun 22, 2009
Financial News

Phynova completes private placement of common stock and warrants

Phynova Group plc (LSE:PYN; Pink:PHNVY), Oxford, U.K. Business: Infectious, Metabolic, Cancer Date completed: 6/15/09 Type: Private placement of common stock and warrants Raised: £3,000 ($4,896) Shares: 50,000 Price: 6p Shares after offering: 31.7 million Investors:...
BioCentury | Nov 24, 2008
Company News

Norgine, Phynova deal

...from Phynova to treat liver disease, after which the companies will consider further collaborative work. Phynova's...
...diagnose liver diseases such as non-alcoholic steatohepatitis (NASH) and hepatitis. Norgine B.V. , Harefield, U.K. Phynova Group plc...
BioCentury | Oct 27, 2008
Clinical News

Phynova preclinical data

...treat MRSA. Phynova licensed the compound from Botanic Century Co. Ltd. (Beijing, China) in 2006. Phynova Group plc...
BioCentury | Aug 28, 2008
Tools & Techniques

Paths of Yeast Assistance

...synthesized at high yields in a well-controlled process. Tony Mills, director of business development at Phynova Group plc...
...research tool for characterizing the enzymes that produce pharmacologically active compounds in a particular plant. Phynova...
...a Phase IIb trial in the near future, though Mills declined to provide a timeline. Phynova...
BioCentury | May 26, 2008
Finance

Midlife crisis

...the costs of Sarbanes-Oxley compliance against low trading volume. One workaround is being pursued by Phynova Group plc...
...expensive burden of compliance with Sarbanes-Oxley," CEO Robert Miller told BioCentury. Originally backed by angels, Phynova...
...is about to enter Phase IIb trials, with proof of concept data expected next year. Phynova...
BioCentury | May 26, 2008
Finance

Late-stage opportunities

...LSE:OXB) -45% Algeta (OSE:ALGETA) -45% Antisoma (LSE:ASM) -41% Exonhit (Euronext:ALEHT) -44% AMT (Euronext:AMT) (B) -37% Phynova...
BioCentury | Dec 10, 2007
Clinical News

Phynova preclinical data

...in Munich. PYN licensed the compound from Botanic Century Co. Ltd. (Beijing, China) in 2006. Phynova Group plc...
BioCentury | Dec 3, 2007
Finance

Ebb & Flow II

...the small molecule CC chemokine receptor 1 (CCR1) antagonist under a 2000 deal (see B25). Phynova...
Items per page:
1 - 10 of 23